Tyrosine Pharma Names Laslie President and CEO

ALBUQUERQUE, N.M. --(BUSINESS WIRE)-- Tyrosine Pharma, Inc. , has announced the appointment of Wayne Laslie as president and chief executive officer. Tyrosine Pharma is a New Mexico -based biotech company that is developing a treatment for stroke based on a derivative of a human protein. Tyrosine Pharma has licensed patented technology for the STEP peptide from STC.UNM created at the University of New Mexico to develop a novel treatment for ischemic stroke. Laslie has more than 30 years of experience in pharmaceutical commercialization. He is the former chief operating officer and chief commercialization officer for Myrexis and Myriad Pharmaceuticals , drug development companies headquartered in Salt Lake City, Utah . Previously, he was head of the commercial group at Otsuka America Pharmaceuticals , where he oversaw the launch of new drugs, including Pletal and Abilify. Prior to Otsuka, Laslie held senior commercial positions in Europe and the United States with the predecessor companies of Sanofi as well as clinical and marketing positions with Pfizer. Laslie joins a strong leadership team at Tyrosine Pharma that includes chief financial officer Alan Kolod , former chief financial officer of Future Medical Systems Group . The inventor of the technology is Dr. Surojit Paul , associate professor of Neurosciences at the University of New Mexico . Current treatment options for blood clot-induced ischemic stroke—which account for 87 percent of strokes—are limited and little used. Tyrosine is developing a post-stroke injection designed to protect patients from brain injury by arresting the progression of brain damage caused by reduced blood flow. The goal is to reduce deaths, long-term disability and the financial impact of stroke. The need for effective stroke therapies is great. Stroke is a leading cause of death in the United States , claiming 130,000 lives each year. The financial impact of stroke is also significant; in 2010 alone, the cost of health care, medications, and missed work to the U.S. economy was $73.7 billion . Stroke is also the leading cause of long-term disability. African-Americans, Hispanics, and Native Americans are disproportionately affected by stroke. About Tyrosine Pharma, Inc. Tyrosine Pharma, Inc. , is a New Mexico -based biotech start-up company and a New Mexico Angels Technology Showcase Company . Visit www.tyrosinepharma.com for additional information. Tyrosine Pharma, Inc. Wayne Laslie , 240-447-7258 [email protected] Alan Kolod , 248-505-4282 [email protected] Melanie Lux , 803-331-4794 [email protected] Source: Tyrosine Pharma, Inc.

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.